Abstract
Most patients with Guillain-Barré syndrome (GBS) respond to treatment with intravenous immunoglobulin, but it is not uncommon for some to continue to deteriorate for a period after treatment has been started. This may reflect the natural history of the disease, or an error in diagnosis. This article reflects my own view of what to do in this situation, with a review of what few data there are to guide decision making.
| Original language | English |
|---|---|
| Pages (from-to) | 227-30 |
| Number of pages | 4 |
| Journal | Practical Neurology |
| Volume | 9 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 1 Aug 2009 |